D2 receptor

Nomenclature: D2 receptor

Family: Dopamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 443 11q23 DRD2 dopamine receptor D2 6,36
Mouse 7 444 9 A5.3 Drd2 dopamine receptor D2 63
Rat 7 444 8q24 Drd2 dopamine receptor D2 6,19
Gene and Protein Information Comments
The human D2 receptor exists as two alternatively spliced isoforms [35]. The 443 amino acid receptor is the long form (D2L). The short form (D2S) is 414 amino acids long.
Previous and Unofficial Names
D2A and D2B
D2(415) and D2(444)
dopamine D2 receptor
D(2) dopamine receptor
dopamine receptor 2
dopamine receptor D2
Drd-2
D2 receptor
D2R
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
Orphanet Gene
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
dopamine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
rotigotine Hs Agonist 10.22 pKi 32
pKi 10.22 (Ki 6x10-11 M) [32]
aripiprazole Rn Partial agonist 9.7 pKi 77
pKi 9.7 [77]
lisuride Hs Partial agonist 9.2 – 9.5 pKi 61
pKi 9.2 – 9.5 [61]
aripiprazole Hs Partial agonist 9.1 pKi 96
pKi 9.1 (Ki 8x10-10 M) [96]
cabergoline Hs Partial agonist 9.0 – 9.2 pKi 61
pKi 9.0 – 9.2 [61]
terguride Hs Partial agonist 9.1 pKi 61
pKi 9.1 [61]
roxindole Hs Partial agonist 8.6 pKi 61
pKi 8.6 [61]
(-)-N-porphynorapomorphine Hs Full agonist 7.5 – 8.9 pKi 34,75
pKi 7.5 – 8.9 [34,75]
ropinirole Hs Agonist 8.14 pKi 39
pKi 8.14 (Ki 7.2x10-9 M) [39]
sumanirole Hs Full agonist 8.1 pKi 59
pKi 8.1 (Ki 9x10-9 M) [59]
bromocriptine Hs Full agonist 7.3 – 8.3 pKi 34,61,75
pKi 7.3 – 8.3 [34,61,75]
apomorphine Rn Partial agonist 7.6 pKi 85
pKi 7.6 [85]
pergolide Hs Full agonist 7.5 – 7.6 pKi 61
pKi 7.5 – 7.6 [61]
bromocriptine Rn Partial agonist 7.3 pKi 85
pKi 7.3 [85]
piribedil Hs Partial agonist 6.8 – 6.9 pKi 61
pKi 6.8 – 6.9 [61]
7-OH-DPAT Hs Full agonist 5.6 – 7.6 pKi 20,34,53
pKi 5.6 – 7.6 [20,34,53]
apomorphine Hs Partial agonist 5.7 – 7.5 pKi 20,34,61,75,84
pKi 5.7 – 7.5 [20,34,61,75,84]
quinpirole Hs Full agonist 4.9 – 7.7 pKi 20,60,66,84-85,91
pKi 4.9 – 7.7 [20,60,66,84-85,91]
pramipexole Hs Full agonist 5.1 – 7.4 pKi 60,75
pKi 5.1 – 7.4 [60,75]
7-OH-DPAT Rn Full agonist 6.2 pKi 28
pKi 6.2 [28]
dopamine Hs Full agonist 4.7 – 7.2 pKi 20,34,75
pKi 4.7 – 7.2 [20,34,75]
PD 128907 Hs Full agonist 5.4 – 6.4 pKi 68,75
pKi 5.4 – 6.4 [68,75]
dopamine Rn Full agonist 5.3 – 6.4 pKi 77,85
pKi 5.3 – 6.4 [77,85]
7-trans-OH-PIPAT Hs Full agonist 5.6 pKi 28
pKi 5.6 [28]
quinelorane Hs Full agonist 5.5 – 5.7 pKi 62,84
pKi 5.5 – 5.7 [62,84]
benzquinamide Hs Agonist 5.4 pKi 37
pKi 5.4 (Ki 3.964x10-6 M) [37]
quinpirole Rn Full agonist 5.2 pKi 85
pKi 5.2 [85]
vilazodone Hs Agonist 6.18 pIC50 40
pIC50 6.18 (IC50 6.66x10-7 M) [40]
View species-specific agonist tables
Agonist Comments
Tergoride is a partial agonist at the D2S receptor and an antagonist at the D2L receptor.
Roxindole is a partial agonist at the D2S receptor and an antagonist at the D2L receptor.
Although benzquinamide has higher affinity for α-adrenoceptors, it is suggested in [37] that it is more likely that drug-induced modulation of D2 receptor activity is responsible for the drug's antiemetic action.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]nemonapride Hs Antagonist 10.9 pKd 54
pKd 10.9 [54]
[3H]spiperone Rn Antagonist 10.2 pKd 19,41,97
pKd 10.2 (Kd 5.7x10-11 M) [19,41,97]
[3H]raclopride Rn Antagonist 8.9 pKd 49
pKd 8.9 (Kd 1.2x10-9 M) [49]
[3H]N-methylspiperone Rn Antagonist 10.7 pKi 77
pKi 10.7 [77]
risperidone Hs Antagonist 9.36 pKi 8
pKi 9.36 (Ki 4.4x10-10 M) [8]
eticlopride Hs Antagonist 9.2 pKi 53,88
pKi 9.2 [53,88]
spiperone Rn Antagonist 8.4 – 9.4 pKi 53,62,85,88
pKi 8.4 – 9.4 [53,62,85,88]
terguride Hs Antagonist 8.9 pKi 61
pKi 8.9 [61]
fluphenazine Hs Antagonist 8.84 pKi 74
pKi 8.84 (Ki 1.44x10-9 M) [74]
nafadotride Rn Antagonist 8.8 pKi 77
pKi 8.8 [77]
lurasidone Rn Antagonist 8.77 pKi 42
pKi 8.77 (Ki 1.68x10-9 M) [42]
olanzapine Hs Antagonist 8.68 pKi 8
pKi 8.68 (Ki 2.1x10-9 M) [8]
mesoridazine Hs Antagonist 8.66 pKi 27
pKi 8.66 (Ki 2.2x10-9 M) [27]
roxindole Hs Antagonist 8.6 pKi 61
pKi 8.6 [61]
ziprasidone Hs Antagonist 8.55 pKi 8
pKi 8.55 (Ki 2.8x10-9 M) [8]
nafadotride Hs Antagonist 8.5 pKi 76
pKi 8.5 [76]
domperidone Rn Antagonist 8.5 pKi 85
pKi 8.5 [85]
raclopride Rn Antagonist 7.7 – 9.3 pKi 77,85
pKi 7.7 – 9.3 [77,85]
prochlorperazine Hs Antagonist 8.44 pKi 10
pKi 8.44 (Ki 3.61x10-9 M) [10]
haloperidol Rn Antagonist 8.3 pKi 85
pKi 8.3 [85]
(+)-sulpiride Hs Antagonist 8.22 pKi 34
pKi 8.22 (Ki 6x10-9 M) [34]
L-741,626 Hs Antagonist 7.9 – 8.5 pKi 38,48
pKi 7.9 – 8.5 [38,48]
domperidone Hs Antagonist 7.9 – 8.4 pKi 34,84
pKi 7.9 – 8.4 [34,84]
haloperidol Hs Antagonist 7.4 – 8.8 pKi 34,53,60,84,89
pKi 7.4 – 8.8 [34,53,60,84,89]
(+)-butaclamol Hs Antagonist 7.5 – 8.7 pKi 20,34,53,88
pKi 7.5 – 8.7 [20,34,53,88]
raclopride Hs Antagonist 8.0 pKi 62
pKi 8.0 [62]
zotepine Hs Antagonist 7.96 pKi 80
pKi 7.96 (Ki 1.1x10-8 M) [80]
cis-flupentixol Hs Antagonist 7.6 – 8.3 pKi 34
pKi 7.6 – 8.3 [34]
Description: Note that this assay uses the cis form of the compound, whereas the approved drug is a racemic mixture of cis and trans molecules.
amisulpride Hs Antagonist 7.8 – 8.0 pKi 55,84-85
pKi 7.9 – 8.0 [55,84]
pKi 7.8 [85]
pimozide Hs Antagonist 7.0 – 8.8 pKi 34,84
pKi 7.0 – 8.8 [34,84]
pimozide Rn Antagonist 7.6 pKi 85
pKi 7.6 [85]
sulpiride Hs Antagonist 7.22 – 7.92 pKi 20
pKi 7.22 – 7.92 (Ki 6x10-8 – 1.2x10-8 M) [20]
metoclopramide Mm Antagonist 7.54 pKi 57
pKi 7.54 (Ki 2.88x10-8 M) [57]
chlorpromazine Rn Antagonist 7.5 pKi 85
pKi 7.5 [85]
chlorpromazine Hs Antagonist 7.0 – 7.6 pKi 34,84
pKi 7.0 – 7.6 [34,84]
quetiapine Hs Antagonist 7.2 pKi 8
pKi 7.2 (Ki 6.9x10-8 M) [8]
(-)-sulpiride Hs Antagonist 6.28 – 8.0 pKi 34,84,88
pKi 6.28 – 8.0 (Ki 5.2x10-7 – 1x10-8 M) [34,84,88]
(+)-sulpiride Rn Antagonist 7.0 pKi 85
pKi 7.0 [85]
(+)-UH232 Hs Antagonist 6.4 – 7.1 pKi 34,85
pKi 6.4 – 7.1 [34,85]
promazine Hs Antagonist 6.52 pKi 21
pKi 6.52 (Ki 3x10-7 M) [21]
(+)-UH232 Rn Antagonist 6.4 pKi 85
pKi 6.4 [85]
clozapine Hs Antagonist 5.8 – 6.8 pKi 34,53,84,88
pKi 5.8 – 6.8 [34,53,84,88]
clozapine Rn Antagonist 6.2 pKi 85
pKi 6.2 [85]
trans flupenthixol Hs Antagonist 5.9 – 6.0 pKi 34
pKi 5.9 – 6.0 [34]
(+)-S-14297 Hs Antagonist 5.5 pKi 62
pKi 5.5 [62]
(+)-SCH-23390 Hs Antagonist 5.3 pKi 34
pKi 5.3 [34]
iloperidone Rn Antagonist 6.96 pIC50 86
pIC50 6.96 (IC50 1.1x10-7 M) [86]
Description: Measuring displacement of [3H]spiperone from rat striatum.
View species-specific antagonist tables
Antagonist Comments
Tergoride and roxindole act as a partial agonists at the D2S receptor and as antagonists at the D2L receptor.
Perphenazine is an antagonist at both the D2S and D2L receptors [87].
The approved drug mesoridazine, although consisting of 4 stereoisomers, appears to be selective for the D2 receptor [27], especially when examining the data for the two highest affinity isomers, compounds 2 and 5. Across the 3 dopamine receptors, compounds 2 and 5 have the same order of potency (D2>D3>D1). The data shown in the table above is for compound 2. Mesoridazine is also a selective antagonist of the serotonin 5-HT2A receptor.
Zotepine has a Ki of 5.4nM for the D2S receptor isoform [80].
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  43,64-65
Secondary Transduction Mechanisms
Transducer Effector/Response
Potassium channel
References:  26
Tissue Distribution
Adrenal cortex.
Species:  Human
Technique:  Autoradiography.
References:  2
Striatum.
Species:  Rat
Technique:  in situ hybridization.
References:  22
Cerebral, mesenteric and renal arteries.
Species:  Rat
Technique:  Autoradiography.
References:  3
Striatonigral neurons.
Species:  Rat
Technique:  Immunofluorescence.
References:  7
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in GH4C1 cells transfected with the D2 receptor.
Species:  Rat
Tissue:  GH4C1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  1
Measurement of prolactin secretion in GH4C1 cells transfected with the D2 receptor.
Species:  Rat
Tissue:  GH4C1 cells.
Response measured:  Inhibition of prolactin secretion.
References:  1
Measurement of voltage-dependent potassium current in NG108-15 cells transfected witht the D2 receptor.
Species:  Rat
Tissue:  NG108-15 cells.
Response measured:  Inhibition of voltage-dependent potassium current.
References:  25
Measurement of activation of potassium channel in rat lactotrophs endogenously expressing the D2 receptor.
Species:  Rat
Tissue:  Lactotrophs.
Response measured:  Activation of potassium channel.
References:  26
Measurement of Ca2+ and cAMP levels in Ltk- cells transfected with both the long and short forms of the human D2 receptor.
Species:  Human
Tissue:  LTK- cells.
Response measured:  Stimulation of calcium mobilisation and cAMP accumulation.
References:  52
Measurement of [3H]thymidine incorporation in CHO cells transfected with the human D2 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  [3H]thymidine incorporation.
References:  51
Measurement of cAMP levels in CHO cells transfected with the human D2 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Inhibition of cAMP accumulation.
References:  51
Measurement of [3H]arachidonic acid release from rat striatal neurons endogenously expressing the D2 receptors.
Species:  Rat
Tissue:  Striatal neurons.
Response measured:  Enhanced [3H]arachidonic acid release.
References:  78
Measurement of cAMP levels in HEK 293 cells transfected with the human D2 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  58,94
Measurement of Cl- currents in Xenopus oocytes transfected with murine D2L and D2S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  83
Measurement of inwardly rectifying K+ currents in Xenopus oocytes transfected with the human D2 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1 channels.
References:  67
Physiological Functions
Stimulation of accumulation of cAMP in membrane particles of the rat kidney medulla.
Species:  Human
Tissue:  Membrane particles of the rat kidney medulla.
References:  4
Inhibits Na+-K+-adenosinetriphosphatase (ATPase) activity when a D1 agonist is co-administered with a D2 agonist.
Species:  Rat
Tissue:  Proximal tubule.
References:  13
Inhibition of (Na+)+K+)ATPase activity via synergism with the D1 receptor.
Species:  Rat
Tissue:  Isolated striatal neurons.
References:  14
Modulation of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  17
Control of renal blood flow.
Species:  Human
Tissue:  In vivo.
References:  18
Modulation of striatal dopamine.
Species:  Rat
Tissue:  In vivo.
References:  46
Reward effects of morphine.
Species:  Rat
Tissue:  In vivo.
References:  56
Blockade enhances learning/memory.
Species:  Rat
Tissue:  In vivo.
References:  82
Physiological Consequences of Altering Gene Expression
D2 receptor knockout mice are insensitive to the cataleptic effects of haloperidol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  15
D2 receptor knockout mice exhibit a decrease in dopamine transporter (DAT) activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
D2 receptor knockout mice display Parkinsonian-like locomotor impairment when compared to the wild type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11,33
D2 receptor knockout mice exhibit hyperprolactinemia (controversy remains as to whether knockout mice display bradykinetic and/or cataleptic behaviour).
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  9,16,44-45,72-73,95
D2 receptor knockout mice exhibit abnormal synaptic plasticity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  24
D2 receptor knockout mice do not exhibit autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  50
D2 receptor knockout mice exhibit d-amphetamine-induced disruption of prepulse inhibition, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  69
D2 receptor knockout mice are insensitive to the hypolocomotor and hypothermic effects of D2/D3 agonists.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16
D2L receptor knockout mice (which still express the short form of the receptor, D2S) exhibit reduced levels of locomotion and rearing behaviour, as well as reduced haloperidol-induced catalepsy and inhibition of locomotor activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  93
D2 receptor knockout mice exhibit reduced ethanol-conditioned place preference.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  30
D2L receptor knockout mice exhibit reduced aggression.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  92
D2 receptor knockout mice do not exhibit autoinhibition of dopamine release.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12,71
D2 receptor knockout mice exhibit increased rates of high-dose cocaine self-administration.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23
D2 receptor knockout mice exhibit reduced locomotor activity and slower acquisition of a place-learning task.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  90
D2 receptor knockout mice exhibit altered dopamine release and uptake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  79
D2 receptor knockout mice exhibit altered GABAergic neurotransmission.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  5
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0004163 abnormal adenohypophysis morphology PMID: 9247267 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2
MGI:94924  MP:0009745 abnormal behavioral response to xenobiotic PMID: 11069937  12650980 
Drd2+|Drd2tm1Yyw Drd2tm1Yyw/Drd2+
B6.129S4-Drd2
MGI:94924  MP:0009745 abnormal behavioral response to xenobiotic PMID: 12650980 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0005535 abnormal body temperature PMID: 18486343 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0000913 abnormal brain development PMID: 11158626 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0005418 abnormal circulating hormone level PMID: 9140068 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002206 abnormal CNS synaptic transmission PMID: 11158626 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0003119 abnormal digestive system development PMID: 15272078 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0001663 abnormal digestive system physiology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0003271 abnormal duodenum morphology PMID: 15272078 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001927 abnormal estrous cycle PMID: 9247268 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0009016 abnormal estrus PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002910 abnormal excitatory postsynaptic currents PMID: 11158626 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0003245 abnormal GABAergic neuron morphology PMID: 17409246 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001406 abnormal gait PMID: 7566118 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0005645 abnormal hypothalamus physiology PMID: 15272078 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0008802 abnormal intestinal smooth muscle morphology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000477 abnormal intestine morphology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0006299 abnormal latent inhibition of conditioning behavior PMID: 15061865 
Adora2atm1Jfc|Drd2tm1Low Adora2atm1Jfc/Adora2atm1Jfc,Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
MGI:94924  MGI:99402  MP:0003313 abnormal locomotor activation PMID: 16280580 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 16280580 
Drd2+|Drd2tm1(IL2RA)Koba Drd2tm1(IL2RA)Koba/Drd2+
B6.129P2-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 14534241 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 11566895  9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 9547254 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 10196569  9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
129S/Sv-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008324 abnormal melanotroph morphology PMID: 9717839 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0006009 abnormal neuronal migration PMID: 17409246 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0004811 abnormal neuron physiology PMID: 11069974 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002803 abnormal operant conditional behavior PMID: 15061865 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0000633 abnormal pituitary gland morphology PMID: 9247267 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0005646 abnormal pituitary gland physiology PMID: 9717839 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003088 abnormal prepulse inhibition PMID: 10341260 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003462 abnormal response to novel odor PMID: 16765459 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0003463 abnormal single cell response PMID: 9140068 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv
MGI:94924  MP:0003463 abnormal single cell response PMID: 14684868 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000470 abnormal stomach morphology PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0000230 abnormal systemic arterial blood pressure PMID: 11566895 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0000230 abnormal systemic arterial blood pressure PMID: 11566895 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0001529 abnormal vocalization PMID: 18382674 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008294 abnormal zona fasciculata morphology PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008295 abnormal zona reticularis morphology PMID: 9717839 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0009546 absent gastric milk in neonates PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001899 absent long term depression PMID: 11158626 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008299 adrenal cortical hyperplasia PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002690 akinesia PMID: 7566118 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002570 alcohol aversion PMID: 10196569 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0001438 aphagia PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001393 ataxia PMID: 10196569 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0001393 ataxia PMID: 10196569 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0005156 bradykinesia PMID: 7566118 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
MGI:94924  MP:0005156 bradykinesia PMID: 11069937 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0005156 bradykinesia PMID: 10391470 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002822 catalepsy PMID: 7566118 
Drd2+|Drd2tm1Ebo Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002822 catalepsy PMID: 7566118 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0005409 darkened coat color PMID: 9140068 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6J
MGI:94924  MP:0003862 decreased aggression towards males PMID: 11303741 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003546 decreased alcohol consumption PMID: 10196569 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
MGI:94924  MP:0001364 decreased anxiety-related response PMID: 11069937 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2
MGI:94924  MP:0001364 decreased anxiety-related response PMID: 11069937 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0001258 decreased body length PMID: 11897683 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001265 decreased body size PMID: 10391470 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0001265 decreased body size PMID: 15272078 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0005534 decreased body temperature PMID: 7566118 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001262 decreased body weight PMID: 7566118 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0001262 decreased body weight PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 16525059 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001262 decreased body weight PMID: 10956362 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0001262 decreased body weight PMID: 11897683 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0003371 decreased circulating estrogen level PMID: 9247268 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0005120 decreased circulating growth hormone level PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0005120 decreased circulating growth hormone level PMID: 11897683 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0004701 decreased circulating insulin-like growth factor I level PMID: 11897683 
+|Cm|Drd2tm1Low Cm/+,Drd2tm1Low/Drd2tm1Low
involves: 101/H * 129S2/SvPas * C3H/HeH * C3H/HeSn * C57BL/6J
MGI:88424  MGI:94924  MP:0005643 decreased dopamine level PMID: 19840852 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0003912 decreased drinking behavior PMID: 7566118 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0003910 decreased eating behavior PMID: 7566118 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0003910 decreased eating behavior PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0008335 decreased gonadotroph cell number PMID: 9247267 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0009293 decreased inguinal fat pad weight PMID: 11897683 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008423 decreased lactotroph cell size PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0003402 decreased liver weight PMID: 11897683 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0008874 decreased physiological sensitivity to xenobiotic PMID: 9247267 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0008874 decreased physiological sensitivity to xenobiotic PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0008874 decreased physiological sensitivity to xenobiotic PMID: 18486343 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0005576 decreased pulmonary ventilation PMID: 10956362 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0009767 decreased sensitivity to xenobiotic induced morbidity/mortality PMID: 18486343 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008329 decreased somatotroph cell number PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0004953 decreased spleen weight PMID: 11897683 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002757 decreased vertical activity PMID: 7566118 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
MGI:94924  MP:0002757 decreased vertical activity PMID: 11069937 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2
MGI:94924  MP:0002757 decreased vertical activity PMID: 11069937 
Drd2+|Drd2tm1Ebo Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002757 decreased vertical activity PMID: 7566118 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0002757 decreased vertical activity PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002757 decreased vertical activity PMID: 9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0002757 decreased vertical activity PMID: 9547254 
Drd2tm2Ebo Drd2tm2Ebo/Drd2tm2Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0009746 enhanced behavioral response to xenobiotic PMID: 11089973 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008366 enlarged adenohypophysis PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0008366 enlarged adenohypophysis PMID: 9247267 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0000646 enlarged adrenocortical cells PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0000636 enlarged pituitary gland PMID: 9247268 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0008370 enlarged pituitary intermediate lobe PMID: 9140068 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000465 gastrointestinal hemorrhage PMID: 15272078 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000465 gastrointestinal hemorrhage PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001505 hunched posture PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001505 hunched posture PMID: 10391470 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001188 hyperpigmentation PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001744 hypersecretion of corticosterone PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001402 hypoactivity PMID: 7566118 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
involves: 129S4/SvJae * C57BL/6
MGI:94924  MP:0001402 hypoactivity PMID: 11069937 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2
MGI:94924  MP:0001402 hypoactivity PMID: 11069937 
Drd2+|Drd2tm1Ebo Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001402 hypoactivity PMID: 7566118 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001402 hypoactivity PMID: 10196569 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0001402 hypoactivity PMID: 10196569 
+|Cm|Drd2tm1Low Cm/+,Drd2tm1Low/Drd2tm1Low